Safety management of anti TROP2 ADCs in patients with breast cancer.
Safety management of TROP2-directed ADCs should be agent-specific, proactive and increasingly individualized and may incorporate pharmacogenomics, longitudinal monitoring, patient-reported outcomes and artificial intelligence to improve toxicity prediction, early detection and adaptive management.